肾移植受者口服霍乱疫苗免疫原性比较:钙调神经磷酸酶抑制剂与霉酚酸酯的对照试验
单中心非随机对照试验比较肾移植受者与健康志愿者接种Dukoral®口服霍乱疫苗后的血清转化率,受者按维持免疫抑制方案分为泼尼松联合钙调神经磷酸酶抑制剂组或联合霉酚酸酯组。结果显示受者总体血清转化率低于健康对照,霉酚酸酯组应答较差,但仍有超过半数受者产生血清转化。
要点
- 肾移植受者接种Dukoral®后血清转化率57%,健康对照81%,相对风险0.70。
- 泼尼松联合钙调神经磷酸酶抑制剂组血清转化率67%,霉酚酸酯组47%。
- 霉酚酸酯组应答较差,但超过半数受者仍可血清转化,口服疫苗不应被放弃。
核心结论
- 肾移植受者对Dukoral®的应答弱于健康对照,血清转化率更低,使用霉酚酸酯者应答尤其差。
- 尽管如此,超过半数肾移植受者仍发生血清转化,口服疫苗不应作为固体器官移植受者的潜在保护工具被舍弃。
研究设计与样本
- 单中心非随机对照临床试验,纳入健康志愿者21例和肾移植受者30例。
- 肾移植受者按维持免疫抑制方案分层:泼尼松联合钙调神经磷酸酶抑制剂组15例,泼尼松联合霉酚酸酯组15例。
- 所有受试者在基线及第14天口服Dukoral®,第0天和第21天采血,主要结局为血清转化。
主要发现
- 肾移植受者血清转化率为57%(标准误9%),健康对照为81%(标准误9%),相对风险0.70(95%CI 0.48-1.02)。
- 泼尼松联合钙调神经磷酸酶抑制剂组血清转化率67%(标准误12%),与对照相比相对风险0.82(95%CI 0.55-1.25)。
- 泼尼松联合霉酚酸酯组血清转化率47%(标准误13%),与对照相比相对风险0.58(95%CI 0.32-1.03)。
- 不良事件为轻至中度且短暂。
关键数值与推荐
- 血清转化定义为抗霍乱毒素B抗体血清IgA滴度升高3倍和/或血清杀弧菌滴度升高4倍。
临床怎么用
- 肾移植受者接种口服霍乱疫苗前应评估免疫抑制方案,使用霉酚酸酯者应答可能较差。
- 不应因免疫抑制而常规放弃口服霍乱疫苗,超过半数受者仍可获得血清转化。
局限性
- 单中心非随机对照试验,样本量较小。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The evidence for recommendations regarding vaccination in solid organ transplant recipients is sparse. There is little data comparing vaccine responses between groups on different immunosuppressive drugs. This study was conducted to evaluate the antibody response to Dukoral® oral cholera vaccine in renal transplant recipients (RTR). METHODS: In a single-center non-randomized controlled clinical trial, healthy volunteers (n = 21) and renal transplant recipients (n = 30) were vaccinated with the oral whole cell/recombinant B subunit cholera vaccine Dukoral® (Valneva Inc., Vienna, Austria). The RTR were stratified according to their maintenance immunosuppressive therapy: either prednisone and a calcineurin inhibitor (cyclosporine A or tacrolimus; P/CNI group; n = 15) or prednisone and mycophenolate (P/MMF group; n = 15). All volunteers ingested Dukoral® at baseline and at day 14. Serum samples were drawn at day 0 and day 21. The primary outcome was seroconversion, defined as either a 3-fold IgA serum titer increase in anti-cholera toxin B antibodies and/or a 4-fold rise in the serum vibriocidal titer. RESULTS: Follow-up was complete. Seroconversion after vaccination was 57% (standard error, SE 9%) in RTR and 81% (SE 9%) in healthy controls (Relative Risk, RR 0.70; 95% CI 0.48-1.02). When stratified according to maintenance immunosuppression, the seroconversion rate was 67% (SE 12%) in the P/CNI group (RR compared with controls 0.82; 95% CI 0.55-1.25) and 47% (SE 13%) in the P/MMF group (RR compared with controls 0.58; 95% CI 0.32-1.03). CONCLUSION: Adverse events were mild to moderate and transient. The response to Dukoral was weaker and the seroconversion rate was lower in renal transplant recipients than in healthy controls. In particular, those using mycophenolate had a poor response. Nevertheless, more than half of the transplant recipients seroconverted. Therefore oral vaccines should not be discarded as a potential tool for protection of solid organ transplant recipients. This trial is registered in clinicaltrials.gov under NCT01109914.
引用
- Jonker EFF, Uijlings MAC, Visser LG, et al. Comparison of the immunogenicity of Dukoral® oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate - A controlled trial. Vaccine. 2019. PMID: 31029516. doi:10.1016/j.vaccine.2019.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。